Business Wire

CMT’s New Report Confirms Increasing Appetite for Connected Insurance in Europe

Share

A large shift in driving habits due to the COVID-19 pandemic has changed how people think about motor insurance across Europe, according to a new study by Cambridge Mobile Telematics (CMT), the world’s leading mobile telematics and analytics provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005773/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

Based on the surveys of 4,000 drivers in France, Germany, Italy and the U.K., the new report shows shifting attitudes towards quoting channels, claims services, pricing models and value-added services, broken down and analysed by location, age and driving behaviour.

The two surveys - taken in January 2020, before the pandemic, and then nine months later in September 2020 - reveal up to 81 percent of the drivers in Europe have changed how they drive because of COVID-19. Now 65 percent are interested in connected insurance, a 32% jump in nine months.

The pandemic has modified commuting patterns and the average drivers now on the road are much younger, a traditionally riskier driving population. With fewer viable public transport commuting options, younger generations are getting behind the wheel to get to work.

Each country lockdown impacted drivers differently. In the U.K., 66 percent of the respondents said their driving patterns changed and that they are now driving less. 29 percent also noted that they drive for different reasons, and on different days. In France, however, the majority (57 percent) have not really changed driving habits, 12 percent even suggested they drove more.

In this context the survey asked respondents about their preferences in terms of quotes, purchase, claims and motor insurance price models. When asked whether they would be likely to switch to behaviour, distance or reward-based insurance , the September survey showed a major shift in drivers’ expectations.

Respondents were overwhelmingly in favour of switching to usage-based insurance (UBI) at the next renewal if the offer was present. Italian drivers were the most likely at 74 percent of the respondents. 63 percent of British and French drivers were ready to switch, and German appetite for connected insurance grew from 47 percent to 58 percent of drivers willing to switch in the nine months between both surveys.

In the full 50-page report you will find:

  • An analysis of the changes in behaviour relating to driving, pricing, buying, and claiming in four European countries by age, gender, type of roads, and premium paid
  • An overview of four markets’ readiness and appetite for connected insurance and digital claims
  • A breakdown of the top value propositions used today, and how preferences have changed since the onset of COVID-19

“The pandemic uncovered challenges few could have predicted. As a result, typical risk models are no longer enough,” commented Ryan McMahon, VP of Insurance & Government Affairs at CMT. “As driving behaviour changes, the ability to predict risk needs to evolve, insurers will find this report can help identify which European drivers to target with new products.”

The Best Connected Insurance Value Propositions for Europe report is available to downloaded from today.

About Cambridge Mobile Telematics

At Cambridge Mobile Telematics, we show up every day to achieve one goal: to make the world's roads and drivers safer. Founded in 2010 based on MIT research, we are now the world's largest mobile telematics provider, powering 65 enterprise programs in more than 28 countries. Our technology serves several million drivers a day through our partnerships with leading insurers, rideshares, cellular carriers and car makers. We deliver cutting-edge technology to solve the most important problems facing mobility today and to improve road safety across the world.

To learn more, visit www.cmtelematics.com and follow CMT on Twitter @cmtelematics.

Contact information

Thomas Hallauer
Cambridge Mobile Telematics
thallauer@cmtelematics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer14.4.2021 16:00:00 EEST | Press release

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years. “Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an import

University of Siena Researchers Demonstrate Rapid UV Disinfection of Operating Rooms Between Surgeries14.4.2021 15:00:00 EEST | Press release

UltraViolet Devices, Inc. (UVDI), a global leader in Ultraviolet Air and Surface disinfection, announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at the Society for Healthcare Epidemiology of America (SHEA) Spring Conference, taking place April 13-16, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005184/en/ In the University of Siena research, the UVDI-360 Room Sanitizer effectively inactivated germs in operating rooms in six minutes. (Photo: Business Wire) In the research, conducted by Dr. Gabriele Messina, Professor of Public Health, University of Siena at the Rugani Hospital Monteriggioni in Siena, the UVDI-360 Room Sanitizer achieved a greater than 97% germ reduction in operating rooms in only six minutes, with two three-minute disinfection cycles run on each side of the operating table. Testing the UVDI-360 R

Amylyx Pharmaceuticals Provides Global Regulatory Update on AMX0035 for ALS14.4.2021 15:00:00 EEST | Press release

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of ALS. The company intends to submit a Marketing Authorization Application (MAA) for AMX0035 to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) by the end of 2021. As previously reported, the company plans to submit a marketing application with Health Canada Q2 2021. The FDA has expressed an interest in seeing data from an additional placebo-controlled clinical trial prior to receiving a New Drug Application (NDA), the vehicle through which a pharmaceutical sponsor formally proposes that the FDA approve an investigational product. To fulfill the FDA’s request and to continue to build upon the growing body of evidence supporting AMX0035 for

Noxopharm Files Septic Shock Treatment Patent for Veyonda®14.4.2021 15:00:00 EEST | Press release

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses. Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock. Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response

HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools14.4.2021 13:00:00 EEST | Press release

HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/ HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of h

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin14.4.2021 12:59:00 EEST | Press release

Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing. “We have decided to make this investment to meet the growing global demand for radiopharmaceutical services in both imaging and therapy products. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate

VertiGIS Acquires Facility Management Software Partner KMS14.4.2021 12:00:00 EEST | Press release

VertiGIS, a leading geographic information systems (GIS) solution provider and software developer, announced today the completed acquisition of longstanding development partner KMS Computer GmbH. KMS is an established and trusted computer-aided facility management (CAFM) software specialist based in Dresden, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005039/en/ KMS by VertiGIS is an established and proven provider of computer-aided facility management (CAFM) software based in Dresden, Germany. KMS is known for its GEBman software and has been supporting municipalities, industrial, service and utility companies, among others, with their facility and document management requirements since 1990. The flexible, end-to-end solutions are based on the latest web technologies and are suitable for internal or mobile use. (Graphic: Business Wire) VertiGIS is backed by global, technology-based investment firm Battery

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom